Observations with Bazoton® in the management of prostatic hyperplasia

Research output: Contribution to journalArticle

10 Citations (Scopus)


Thirty patients with prostatic hyperplasia stages I and II were administered Bazoton® capsules (extract of Radix Urticae) for an average period of 3.5 months. Residual urine, mean and maximal flow were measured before and after treatmet. A significant decrease in the volume of residual urine was found. Increase in mean urinary flow was also significant. Maximal urinary flow increased in 50% of the cases. A marked subjective relief was reported by the patients. Bazoton is regarded as suitable for the conservative treatment of prostatic hyperplasia stages I and II.

Original languageEnglish
Pages (from-to)293-297
Number of pages5
JournalInternational urology and nephrology
Issue number3
Publication statusPublished - Sep 1 1987

ASJC Scopus subject areas

  • Nephrology
  • Urology

Fingerprint Dive into the research topics of 'Observations with Bazoton<sup>®</sup> in the management of prostatic hyperplasia'. Together they form a unique fingerprint.

  • Cite this